The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

The ROBO Global Healthcare Technology & Innovation Index offers unique, targeted exposure to innovators. Click to read.

Another notable valuation metric for PBH is its P/B ratio of 2.28. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total ...

PBH currently has a forward P/E ratio of 16.76, while SYK has a forward P/E of 25.04. We also note that PBH has a PEG ratio of 2.39. This metric is used similarly to the famous P/E ratio, but the ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

Tyrosine Protein Kinase SYK overview. Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, ...

The team, which published its study, “Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in ...

Block of Syk/Calcineurin/NFAT signalling facilitates murine iPSC induction via increased cysteine biosynthesis. image. ... In addition, genetically knocking down or knocking out Syk gene by shRNA or ...

1. Gene and Cell therapy. This research program is related to the development of new gene medicines mainly based on synthetic oligo-nucleotides (ONs). ONs are short pieces of genetic material, which ...